Age-related Features of the Cytological Diagnosis of Cervical Dysplasia of Different Degrees

Maria P. Kirillina, Sargylana I. Sofronova, Irina V. Kononova, Anna K. Ivanova, Elena L. Lushnikova

International Journal of Biomedicine. 2019;9(4):324-328.
DOI: 10.21103/Article9(4)_OA10
Originally published December 15, 2019


The purpose of this study was to investigate the incidence of cervical intraepithelial neoplasia (CIN) and cervical cancer (CC) in women of different age groups who underwent cervical cytological testing from 2016 to 2018. According to our study, the frequency of CD incidence was inversely dependent on the degree of dysplasia in all age groups of women receiving survey from 2016 to 2018. The CIN1 incidence rate increased from 2016 to 2018, while the rate of CIN 2, CIN 3 and CC decreased. An analysis of the distribution patterns of CIN 1, CIN 2, CIN 3 and CC according to age revealed that the peak ages of the CIN1-3 incidence was 26-35 years. In the age group of 46-55 years, there was a sharp increase in CC—by 2.5 times compared with the age groups of 26-35 years and 36-45 years. Although the peak ages of CC incidence was ≥56 years. The peak ages of the indirect signs of HPV infection were 18-29 years and 30-44 years, characterizing the peculiarity of the immune status of these age groups. Thus, the peak age group in which women develop both CIN1 and CIN2+ is 26-35.  Patient’s age has a considerable influence on the natural history of CIN—independent of CIN grade and HPV high-risk infection.

cervical intraepithelial neoplasia • cervical cancer • human papillomavirus
  1. Kaprin AD, Starinsky VV, Petrova GV. Malignant neoplasms in Russia in 2016 (morbidity and mortality). M.: P. A. Hertsen Moscow Oncology Research Center (branch of FSBI NMRRC of the Ministry of Health of Russia); 2018. [In Russian].
  2. Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003;348(6):518–27.
  3. Darragh TM, Colgan TJ, Cox JT, Heller DS, Henry MR, Luff RD, et al. The lower anogenital squamous terminology standardization project for HPV-associated lesions: background and consensus recommendations from the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology. Arch Pathol Lab Med. 2012;136(10):1266-97.
  4. Moscicki AB, Shiboski S, Broering J, Powell K, Clayton L, Jay N, Darragh TM, et al. The natural history of human papillomavirus infection as measured by repeated DNA testing in adolescent and young women. J Pediatr. 1998:132(2):277–84.
  5. World Health Organization. WHO guidelines for treatment of cervicalintraepithelial neoplasia 2–3 and adenocarcinoma in situ. Geneva: World Health Organization; 2014. Available at:
  6. Arbyn M, Ronco G, Anttila A, Meijer CJ, Poljak M, Ogilvie G, et al. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer. Vaccine. 2012;30 Suppl 5:F88-99. doi: 10.1016/j.vaccine.2012.06.095.
  7. De Vuyst H, Mugo NR, Chung MH, McKenzie KP, Nyongesa-Malava E, Tenet V, et al.Prevalence and determinants of human papillomavirus infection and cervical lesions in HIV-positive women in Kenya. Br J Cancer. 2012;107(9):1624-30. doi: 10.1038/bjc.2012.441.
  8. Joshi S, Sankaranarayanan R, Muwonge R, Kulkarni V, Somanathan T, Divate U. Screening of cervical neoplasia in HIV-infected women in India. AIDS. 2013;27(4):607-15. doi: 10.1097/QAD.0b013e32835b1041.
  9.  Denny L, Boa R, Williamson AL, Allan B, Hardie D, Stan R, Myer L. Human papillomavirus infection and cervical disease in human immunodeficiency virus-1-infected women. Obstet Gynecol. 2008;111(6):1380-7. doi: 10.1097/AOG.0b013e3181743327.
  10. Zhang HY, Tiggelaar SM, Sahasrabuddhe VV, Smith JS, Jiang CQ, Mei RB, et al. HPV prevalence and cervical intraepithelial neoplasia among HIV-infected women in Yunnan Province, China: a pilot study. Asian Pac J Cancer Prev. 2012;13(1):91-6.
  11. Garutti P, Borghi C, Bedoni C, Bonaccorsi G, Greco P, Tognon M, et al. HPV-based strategy in follow-up of patients treated for high-grade cervical intra-epithelial neoplasia: 5-year results in a public health surveillance setting. Eur J Obstet Gynecol Reprod Biol. 2017;210:236-241. doi: 10.1016/j.ejogrb.2016.12.018.
  12. Insinga RP, Glass AG, Rush BB. Diagnoses and outcomes in cervical cancer screening: a population-based study. Am J Obstet Gynecol. 2004;191(1):105–13. 
  13.  Henk HJ, Insinga RP, Singhal PK, Darkow T. Incidence and costs of cervical intraepithelial neoplasia in a US commercially insured population. J Low Genit Tract Dis. 2010; 14(1):29-36. doi: 10.1097/LGT.0b013e3181ac05e9.
  14. The American Cancer Society medical and editorial content team. Key Statistics for Cervical Cancer Available at:
  15. Boda D, Docea AO, Calina D, Ilie MA, Caruntu C, Zurac S, et al. Human papilloma virus: Apprehending the link with carcinogenesis and unveiling new research avenues (Review). Int J Oncol. 2018;52(3):637-655. doi: 10.3892/ijo.2018.4256.
  16. Stokley S, Jeyarajah J, Yankey D, Cano M, Gee J, Roark J, et al.; Immunization Services Division, National Center for Immunization and Respiratory Diseases, CDC; Centers for Disease Control and Prevention (CDC). Human papillomavirus vaccination coverage among adolescents, 2007-2013, and postlicensure vaccine safety monitoring, 2006-2014--United States. MMWR Morb Mortal Wkly Rep. 2014;63(29):620-4.
  17. Doorbar J, Quint W, Banks L, Bravo IG, Stoler M, Broker TR, Stanley MA. The biology and life-cycle of human papillomaviruses. Vaccine. 2012 Nov 20;30 Suppl 5:F55-70. doi: 10.1016/j.vaccine.2012.06.083.
  18. Krawczyk E, Suprynowicz FA, Liu X, Dai Y, Hartmann DP, Hanover J, Schlegel R. Koilocytosis: a cooperative interaction between the human papillomavirus E5 and E6 oncoproteins. Am J Pathol. 2008;173(3):682-8. doi: 10.2353/ajpath.2008.080280.
  19. Bekos C, Schwameis R, Heinze G, Gärner M, Grimm C, Joura E, et al. Influence of age on histologic outcome of cervical intraepithelial neoplasia during observational management: results from large cohort, systematic review, meta-analysis. Sci Rep. 2018;8(1):6383. doi: 10.1038/s41598-018-24882-2.
  20. World Health Organization. WHO guidelines for screening and treatment of precancerous lesions for cervical cancer prevention. Geneva: World Health Organization; 2013. Available at:

Download Article
Received October 7, 2019.
Accepted November 24, 2019.
©2019 International Medical Research and Development Corporation.